US 12364711 B1Patent grantUnited States

Manganese-Oxide Nanocomposite for Cancer Cell Studies

Official patent title

Inhibition of cancer cell viability

Arabic title: تثبيط حيوية الخلايا السرطانية

Invention

Problem

Cancer treatment can be limited by toxicity, inadequate targeting, poor bioavailability, and resistance, motivating investigation of new materials that affect tumor-cell viability.

Why it matters

Identifying selective anticancer candidates is valuable, but reduced viability in cultured cells is only an early preclinical signal and cannot establish therapeutic benefit.

Approach

The method contacts cancer cells with a graphitic C3N4, MnO2, and MgAl2O4 nanocomposite at defined mass ratios and concentrations. The disclosure states at least 85% growth inhibition and identifies HepG-2 liver and MCF-7 breast carcinoma cell models.

Who may benefit

Potential beneficiaries include oncology research laboratories, nanomedicine groups, preclinical screening programs, materials scientists studying cell interactions, and pharmaceutical discovery teams.

Potential value

The disclosure links a defined carbon-nitride and mixed-oxide nanocomposite to specified cancer-cell contact conditions and early viability endpoints.

Background

Conventional cancer therapies can face dose-limiting toxicity, resistance, poor solubility, and nonselective exposure. Nanomaterials are investigated as carriers or active agents because size, surface, and composition can influence cellular interactions. The publication proposes a graphitic-carbon-nitride, manganese-dioxide, and magnesium-aluminate composite and states growth inhibition in HepG-2 and MCF-7 cultures. The supplied evidence is limited to patent-described in-vitro cell viability and material characterization; it does not establish selectivity over normal cells, mechanism, biodistribution, animal safety, efficacy, or clinical outcomes.

Technology overview

The nanocomposite contains graphitic C3N4, MnO2, and MgAl2O4 at an approximate 5–15:2–7:75–95 mass relationship and is contacted with cells at about 10–500 μg/mL. The disclosure gives narrower concentration ranges for HepG-2 and MCF-7 cells and states at least 85% growth inhibition. BET area, pore diameter and volume, interplanar spacings, XRD phase peaks, and nanosheet morphology characterize the material. The evidence does not show a formulated medicine or an administered in-vivo treatment.

Potential applications

Preclinical in-vitro cancer-cell viability research.
Screening nanocomposites against liver and breast carcinoma cell lines.
Material-cell interaction studies in nanomedicine laboratories.
Early anticancer lead and mechanism exploration.

Evidence-supported advantages

The three-component mass relationship is defined.
Cell-contact concentration ranges are specified.
Two named human carcinoma cell models are identified.
Phase, pore, surface, and nanoscale structural characteristics are described.

Development stage

Patent-described in-vitro cancer-cell viability testing and laboratory material characterization are available; normal-cell, in-vivo, toxicology, and clinical validation are not established.

Commercial opportunity

The material is an early preclinical research candidate, not an established cancer therapy. Translation requires independent assay replication, normal-cell selectivity, mechanism and genotoxicity studies, dose and formulation development, stability, pharmacokinetics, biodistribution, clearance, animal efficacy and toxicology, scalable manufacturing, regulatory review, and ultimately controlled clinical trials.

Patent classifications

WIPO IPC

A61K33/00Preparations for medical, dental or toiletry purposes
A61K33/08Preparations for medical, dental or toiletry purposes

CPC

A61K33/08Preparations for medical, dental or toiletry purposes
A61K33/32Preparations for medical, dental or toiletry purposes
A61K33/00Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations

Inventors

First inventorMohamed Khairy Abdel Fattah Omran
InventorBabiker Yagoub Elhadi Abdulkhair

Keywords

cancer cell viability
graphitic carbon nitride
manganese dioxide
magnesium aluminate
nanocomposite
HepG-2
MCF-7
in-vitro

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.